In a recent study posted to the bioRxiv* preprint server, researchers compared the immunogenicity of, and reactogenicity to, the BNT162b2 vaccine, a coronavirus disease 2019 (COVID-19) messenger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results